We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

Amgen Czech Republic

Pharmaceutical > Czech Republic > Amgen Czech Republic
Change Company
Amgen Czech Republic

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo

Read more »
Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases

Buy all financials of Amgen Czech Republic

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Gross Profit CZK mil
EBIT CZK mil
Net Profit CZK mil
ROE %
EBIT Margin %
Net Margin %
Employees
...             422 416 468 637 604    
...             177 154 159 169 159    
...             56.3 35.0 38.9 52.5 44.3    
...             46.2 28.3 28.7 40.5 35.8    
...             31.6% 15.4% 15.8% 21.7% 18.4%    
...             13.3% 8.40% 8.32% 8.25% 7.34%    
...             10.9% 6.81% 6.14% 6.36% 5.93%    
              72.0 66.0 67.0 65.0 65.0    

balance sheet

...             227 259 218 267 276    
...             6.77 5.13 4.91 2.67 1.43    
...             219 253 213 263 274    
...             169 198 167 207 183    
...             57.1 60.8 51.9 60.3 93.3    
...             0.029 0.029 0.029 0.000 0.000    
...             55.7 59.2 51.8 59.7 92.9    
...             0.000 0.000 -0.005 0.709 1.53    
...             0.000% 0.000% -0.133% 18.6% 38.7%    
... ... ... ... ... ... ... ... ... 1,890% 11.3% 0.592%   ...

cash flow

... ...           52.0 20.0 81.2 -43.7 130    
... ...           -52.0 -20.0 -21.0 44.7 -69.9    
... ...           0.000 0.000 -60.0 -0.028 -60.0    
... ...           0.000 0.000 0.251 0.926 -0.159    

Download Data
income statement Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Cost of Goods & Services CZK mil
Gross Profit CZK mil
Staff Cost CZK mil
Other Cost CZK mil
EBITDA CZK mil
Depreciation CZK mil
EBIT CZK mil
Financing Cost CZK mil
Extraordinary Cost CZK mil
Pre-Tax Profit CZK mil
Tax CZK mil
Minorities CZK mil
Net Profit CZK mil
Dividends CZK mil
...             422 416 468 637 604    
...             245 262 309 467 445    
...             177 154 159 169 159    
...             111 106 102 98.2 96.4    
...             7.27 11.1 15.8 16.7 16.4    
...             58.3 37.3 41.1 54.4 46.3    
...             2.02 2.31 2.21 1.94 1.93    
...             56.3 35.0 38.9 52.5 44.3    
...             -0.196 -0.315 0.274 2.25 0.330    
...             0.000 0.000 0.000 0.000 0.000    
...             56.5 35.3 38.6 50.2 44.0    
...             10.3 6.94 7.90 9.76 8.17    
...             0.000 0.000 0.000 0.000 0.000    
...             46.2 28.3 28.7 40.5 35.8    
... ... ... ... ... ... ... ... ... ... ... 0.000   ...

growth rates

... ...           17.8% -1.40% 12.4% 36.0% -5.06%    
... ...           8.84% -1.44% 0.493% -2.18% -1.76%    
... ...           50.4% -36.1% 10.4% 32.3% -15.0%    
... ...           56.9% -37.9% 11.3% 34.9% -15.5%    
... ...           55.9% -37.5% 9.53% 30.0% -12.4%    
... ...           57.1% -38.7% 1.42% 40.8% -11.4%    

ratios

...             31.6% 15.4% 15.8% 21.7% 18.4%    
... ...           48.3% 26.3% 33.8% 44.9% 36.6%    
...             41.9% 37.0% 33.9% 26.6% 26.3%    
...             13.8% 8.95% 8.79% 8.55% 7.66%    
...             13.3% 8.40% 8.32% 8.25% 7.34%    
...             10.9% 6.81% 6.14% 6.36% 5.93%    
... ... ... ... ... ... ... ... ... ... ... 0.000%   ...
... ... ... ... ... ... ... ... ... 1,890% 11.3% 0.592%   ...
...             0.000 0.000 -0.005 0.709 1.53    

Download Data
balance sheet Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

balance sheet

...             6.77 5.13 4.91 2.67 1.43    
...             5.47 3.81 2.82 2.67 1.43    
...             1.29 1.32 1.25 1.81 1.35    
... ... ... ... ... ... ... ... ... ... 0.857 0.081    
...             219 253 213 263 274    
...             0.000 0.000 0.000 0.000 0.000    
...             99.5 112 48.4 137 81.9    
...             0.000 0.000 0.251 1.18 1.02    
...             227 259 218 267 276    
...             169 198 167 207 183    
...             0.000 0.000 0.000 0.000 0.000    
...             57.1 60.8 51.9 60.3 93.3    
...             0.029 0.029 0.029 0.000 0.000    
...             0.000 0.000 0.029 0.000 0.000    
...             0.000 0.000 0.000 0.000 0.000    
...             55.7 59.2 51.8 59.7 92.9    
...             0.000 0.000 0.000 39.8 71.8    
...             7.08 0.645 0.029 12.6 14.4    
...             1.27 1.54 0.000 0.000 0.000    
...             227 259 218 267 276    

growth rates

... ...           36.5% 14.1% -15.6% 22.4% 3.28%    
... ...           37.5% 16.7% -15.8% 24.3% -11.7%    
... ...           ... ... ... -17,482% 83.3%    
... ... ... ... ... ... ... ... ... ... 137,021% 80.5%   ...

ratios

...             0.000 0.000 0.029 39.8 71.8    
...             0.000 0.000 -0.222 38.6 70.7    
...             92.4 111 48.4 124 67.4    
...             99.2 117 53.3 127 68.9    
...             0.000% 0.000% -0.133% 18.6% 38.7%    
... ... ... ... ... ... ... ... ... 1,890% 11.3% 0.592%   ...

Download Data
cash flow Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

cash flow

...             46.2 28.3 28.7 40.5 35.8    
...             2.02 2.31 2.21 1.94 1.93    
... ...           11.5 8.40 -12.8 -10.3 35.2    
... ...           -7.70 -19.0 63.1 -75.8 56.8    
... ...           52.0 20.0 81.2 -43.7 130    
... ...           -2.00 -1.00 -1.15 -0.543 -0.695    
... ...           -50.0 -19.0 -19.8 45.2 -69.3    
... ...           -52.0 -20.0 -21.0 44.7 -69.9    
... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ...    
... ...           0.000 0.000 0.029 39.7 32.0    
... ...           0.000 0.000 -60.0 -0.028 -60.0    
... ...           0.000 0.000 0.251 0.926 -0.159    

ratios

...             86.0 98.3 37.8 78.4 49.5    
...             0.000 0.000 0.000 0.000 0.000    
...             10.5 0.898 0.034 9.84 11.8    
...             75.5 97.4 37.7 68.6 37.6    
...             48.2 30.6 31.0 42.4 37.8    
... ...           0.000 0.000 60.3 0.954 59.8    

Download Data
other data Unit
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

other data

...             23.5% 11.7% 12.0% 16.7% 13.2%    
...             41.9% 37.0% 33.9% 26.6% 26.3%    
              72.0 66.0 67.0 65.0 65.0    
...             7,282 6,827 6,457 5,890 5,178    
...             128,795 133,538 126,332 125,883 123,604    
...             30.4% 27.7% 23.7% 16.8% 17.2%    
...             18.2% 19.7% 20.4% 19.4% 18.6%    
...             190 184 176 176 166    
...             233 232 292 460 438    
... ...           0.474% 0.240% 0.245% 0.085% 0.115%    

Download Data
Comparison of 9 Companies in Czech Pharmaceutical Companies

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file

Read more »

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file contains data of following companies:

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

Download a sample excel file attached to see more details. On purchase, the hidden cells will be unlocked and all available data wll be visible.

Amgen Czech Republic in Numbers

This Annual Statistical Dossier offers a summary of Amgen Czech Republic's performance between 2004 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested

Read more »

This Annual Statistical Dossier offers a summary of Amgen Czech Republic's performance between 2004 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

If you are interested in the company’s quarterly figures, please refer to the company’s Quarterly Statistical Dossier.

Amgen Czech Republic at a Glance

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical

Read more »

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

This report offers a summary of the company's performance in 2005-2012. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Amgen Czech Republic in Numbers

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical

Read more »

Amgen Czech Republic is a Czech Republic-based subsidiary of the global pharmaceutical company Amgen. Amgen entered the Czech market in May 2004 folowing the entrance of the country into the EU. Now, the Czech subsidiary employes around 60 people with sales accounting for over USD 20 mil. Amgen (Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

This excel file offers a summary of the company's performance in 2005-2012. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Amgen Czech Republic made a net profit of CZK 37.8 mil in 2017, up 20.0% when compared to the last year. Total sales reached CZK 417 mil, which is down 33.4% when compared to the previous year.

Historically, the company’s

Read more »

Amgen Czech Republic made a net profit of CZK 37.8 mil in 2017, up 20.0% when compared to the last year. Total sales reached CZK 417 mil, which is down 33.4% when compared to the previous year.

Historically, the company’s net profit reached an all time high of CZK 46.2 mil in 2011 and an all time low of CZK 9.88 mil in 2007.

In terms of sales, Amgen Czech Republic reached an all time high of CZK 637 mil in 2014 and an all time low of CZK 135 mil in 2006.

Amgen Czech Republic's net profit has grown 5.94% a year on average in the last five years while sales have increased by 0.037% a year since 2012.

The firm generated its shareholders an average return on invested capital of 29.5% in the last five years.

You can see all the company’s data at Amgen Czech Republic Profile, or you can download a report on the company in the report section.

Amgen Czech Republic made a net profit of CZK CZK 37.8 mil under revenues of CZK 417 mil in 2017, up 20% and -33.4%, respectively, when compared to the last year.

This translates into a net margin of 9.06%. Historically, the firm’s

Read more »

Amgen Czech Republic made a net profit of CZK CZK 37.8 mil under revenues of CZK 417 mil in 2017, up 20% and -33.4%, respectively, when compared to the last year.

This translates into a net margin of 9.06%. Historically, the firm’s net margin reached an all time high of 11.3% in 2008 and an all time low of 4.61% in 2005. The average net margin in the last five years amounted to 6.51%.

On the operating level, EBITDA margin reached 11.6% and EBIT amounted to 11.8% of sales in 2017.

You can see all the company’s data at Amgen Czech Republic Profile, or you can download a report on the company in the report section.

Amgen Czech Republic made a net profit of CZK 37.8 mil under revenues of CZK 417 mil in 2017, up 20.0% and -33.4%, respectively, when compared to the last year. This translates into a net margin of 9.06%.

Historically, the firm’s

Read more »

Amgen Czech Republic made a net profit of CZK 37.8 mil under revenues of CZK 417 mil in 2017, up 20.0% and -33.4%, respectively, when compared to the last year. This translates into a net margin of 9.06%.

Historically, the firm’s net profit reached an all time high of CZK 46.2 mil in 2011 and an all time low of CZK 5.00 mil in 2005. Since 2012, the firm's net profit has increased 33.4% or 5.94% a year on average.

On the operating level, EBITDA reached CZK 49.0 mil, up 26.3% when compared to the previous year. Over the last five years, company's EBITDA has grown 5.65% a year on average.

You can see all the company’s data at Amgen Czech Republic Profile, or you can download a report on the company in the report section.

Amgen Czech Republic's net debt reached CZK -0.283 mil and accounted for -0.147% of equity at the end of 2017. The ratio is down 17.4% when compared to the previous year.

Historically, the firm’s net debt to equity reached an

Read more »

Amgen Czech Republic's net debt reached CZK -0.283 mil and accounted for -0.147% of equity at the end of 2017. The ratio is down 17.4% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 38.7% in 2015 and an all time low of -80.1% in 2005.

When compared to EBITDA, net debt amounted to -0.006x at the end of the year. The ratio reached an all time high of 1.53 in 2015 and an all time low of -2.63 in 2008.

You can see all the company’s data at Amgen Czech Republic Profile, or you can download a report on the company in the report section.

See all charts of the company »
Amgen CR's net profit rose 20.0% to CZK 37.8 mil in 2017
Amgen CR's net profit rose 20.0% to CZK 37.8 mil in 2017
Amgen CR's employees rose 7.94% to 68.0 in 2017
Amgen CR's Total Cash From Operations rose 1,003% to CZK 118 mil in 2017
Amgen CR's ROCE fell 20.6% to 14.2% in 2017
Amgen CR's Capital Expenditures fell 66.3% to CZK 0.135 mil in 2017
Amgen CR's Net Debt/EBITDA rose 16.7% to -0.006 in 2017
Amgen CR's Cash & Cash Equivalents rose 5.20% to CZK 0.283 mil in 2017
Amgen CR's Net Margin rose 80.1% to 9.06% in 2017